VSTM logo

VSTM
Verastem Inc

24,060
Mkt Cap
$427.82M
Volume
2.44M
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.33
VSTM Fundamentals
Price
$5.81
Prev Close
$5.68
Open
$5.74
50D MA
$6.67
Beta
1.33
Avg. Volume
1.55M
EPS (Annual)
-$3.66
P/B
-24.42
Rev/Employee
$128,205.13
$138.07
Loading...
Loading...
News
all
press releases
Verastem Q4 Earnings Call Highlights
Verastem (NASDAQ:VSTM) executives said the company's transition to a commercial-stage business accelerated in 2025 following FDA approval of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates
Verastem (VSTM) delivered earnings and revenue surprises of -2.04% and +0.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5h ago
News Placeholder
Verastem (NASDAQ:VSTM) Issues Earnings Results
Verastem (NASDAQ:VSTM - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating analysts...
MarketBeat·5h ago
News Placeholder
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three...
Business Wire·6h ago
News Placeholder
Verastem (VSTM) Projected to Post Earnings on Wednesday
Verastem (NASDAQ:VSTM) will be releasing its Q4 2025 earnings after the market closes on Wednesday, March 4. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...
Business Wire·15d ago
News Placeholder
What Makes Verastem (VSTM) a New Buy Stock
Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·15d ago
News Placeholder
Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts
Verastem (NASDAQ:VSTM) executives highlighted commercial momentum for the company's newly launched ovarian cancer therapy and laid out near-term clinical catalysts across its RAS-pathway pipeline...
MarketBeat·17d ago
News Placeholder
FY2025 EPS Estimates for Verastem Increased by HC Wainwright
Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Verastem in a note issued to investors on Thursday, February...
MarketBeat·24d ago
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports...
MarketBeat·25d ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.